Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tilsotolimod - Aceragen

Next Previous
Drug Profile

Tilsotolimod - Aceragen

Alternative Names: IMO-2125; IMO-2125 sodium; Tilsotolimod sodium

Latest Information Update: 18 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer AbbVie; Aceragen; Bristol-Myers Squibb
  • Class Antineoplastics; Antivirals; Immunotherapies; Oligodeoxyribonucleotides
  • Mechanism of Action Immunologic cytotoxicity; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Head and neck cancer; Hepatitis C; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 31 May 2024 Efficacy data from the phase III ILLUMINATE-301 in Malignant melanoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 13 Apr 2023 Tilsotolimod is available for licensing as of 01 Dec 2021. https://www.aceragen.com/
  • 28 Feb 2023 No recent reports of development identified for phase-I development in Squamous-cell-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in France (Intratumoural, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top